MBNL1 Antibody #94633
- WB
- IP
Supporting Data
REACTIVITY | H M Mk |
SENSITIVITY | Endogenous |
MW (kDa) | 42 |
SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- Mk-Monkey
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Immunoprecipitation | 1:50 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human MBNL1 protein. Antibodies are purified by peptide affinity chromatography.
Background
Alternative splicing is a crucial biological process that promotes protein diversity and provides cells with an additional mechanism to regulate the expression of tissue-specific protein isoforms. Muscleblind-like proteins (MBNLs) are one such protein family responsible for tissue-specific alternative splicing regulation. MBNLs bind pre-mRNA through an evolutionarily conserved zinc finger domain, and act as either activators or repressors of splicing on specific pre-mRNA targets by promoting the inclusion or exclusion of exons (1). MBNLs are functionally antagonistic to CUG-BP and ETR-3-like factors (CELF proteins) that also control pre-mRNA splicing. The interplay between MBNL and CELF activity plays a key role in development, where predominant MBNL activity promotes adult differentiation, and predominant CELF activity promotes embryonic splicing patterns (1). Three MBNL homologs are expressed in humans (MBNL1, MBNL2, and MBNL3) that share similar structure and function, yet differ in their tissue- and developmental stage-specific expression patterns (2). MBNL1 is the predominant isoform in the majority of tissue, including muscle, and is therefore the most well characterized. MBNL2 is the predominant homolog in brain, and exhibits increased expression upon functional loss of MBNL1 in other tissue types, suggesting a compensatory role (3). MBNL3 appears to play a more specialized role, where it inhibits muscle differentiation in muscle precursor cells (4). Functional loss of MBNLs is observed in myotonic dystrophy (DM), where pathological repeats in the 3’-UTR of the myotonic dystrophy protein kinase (DMPK) gene or intron 1 of the cellular nucleic acid binding protein (CNBP) gene result in toxic RNA hairpins that sequester MBNLs in nuclear foci. This loss of available MBNLs causes an adult-to-fetal shift in alternative splicing patterns and ultimately results in respiratory and cardiac complications observed in DM patients (2,5).
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.